ViroCell Biologics has appointed Susan B. Nichols to its senior management team as its Chief Business Officer.
The London-headquartered CDMO is addressing the global viral vector supply/demand imbalance that constrains the timely manufacture of novel cell and gene therapies. It focuses exclusively on the design and GMP manufacture of viral vectors and gene modified cells for clinical trials.
“ViroCell aims to be the global viral vector supplier of choice for the translational development phase of novel cell and gene therapies,” says the company. “The appointment of Susan as CBO is a significant milestone in ViroCell’s continuing operational development as a future leader in the clinical trial CDMO market and her appointment brings with it, Susan’s passion to assist clients in accelerating their innovative product candidates into and through clinical trials.”
Nichols has a distinguished track record as an executive and business development professional and currently sits on the Board of Directors of the Alliance for Regenerative Medicine (“ARM”), the leading international advocacy organization dedicated to realizing the promise of regenerative medicines and advanced therapies. She is also Co-Chair of its Accelerator Committee and Co-Chair of ARM’s Womens’ Executive Forum.
Most recently, Nichols was an executive officer at Propel BioSciences, Cary N.C. as part of the Entrepreneurial Consulting Team, supporting the business development and funding needs of early-stage biotech and pharmaceutical companies. Prior to that, she was CEO of Falcon Therapeutics, Durham N.C., an early-stage gene modified cell therapy company focused on solid tumors. She joined Falcon in 2018 to apply her manufacturing, operational and fundraising experience to take a promising academic candidate to clinical trial readiness.